EA201990699A1 - SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION - Google Patents

SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION

Info

Publication number
EA201990699A1
EA201990699A1 EA201990699A EA201990699A EA201990699A1 EA 201990699 A1 EA201990699 A1 EA 201990699A1 EA 201990699 A EA201990699 A EA 201990699A EA 201990699 A EA201990699 A EA 201990699A EA 201990699 A1 EA201990699 A1 EA 201990699A1
Authority
EA
Eurasian Patent Office
Prior art keywords
menin
spirobicyclic
inhibitors
mll interaction
compounds
Prior art date
Application number
EA201990699A
Other languages
Russian (ru)
Inventor
Патрик Рене Анжибо
Винет Панде
Барбара Херкерт
Дэниел Джейсон Кроски
Оливье Алексис Жорж Керолль
Изабелль Ноэлль Констанс Пилатт
Аарон Натаниэль Патрик
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201990699A1 publication Critical patent/EA201990699A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к фармацевтическим средствам, пригодным для терапии и/или профилактики у млекопитающего, и, в частности, к спиробициклическим соединениям, фармацевтической композиции, содержащей такие соединения, и к их применению в качестве ингибиторов белок-белковых взаимодействий менин-MLL, пригодных для лечения заболеваний, таких как рак, миелодиспластический синдром (MDS) и диабет.The present invention relates to pharmaceuticals suitable for the treatment and / or prophylaxis in a mammal, and in particular to spirobicyclic compounds, a pharmaceutical composition containing such compounds, and their use as menin-MLL protein-protein interaction inhibitors suitable for treating diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes.

EA201990699A 2016-10-05 2017-09-13 SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION EA201990699A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16192431 2016-10-05
PCT/EP2017/073004 WO2018050686A1 (en) 2016-09-14 2017-09-13 Spiro bicyclic inhibitors of menin-mll interaction

Publications (1)

Publication Number Publication Date
EA201990699A1 true EA201990699A1 (en) 2019-09-30

Family

ID=57083210

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990699A EA201990699A1 (en) 2016-10-05 2017-09-13 SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION

Country Status (4)

Country Link
CA (1) CA3033239A1 (en)
EA (1) EA201990699A1 (en)
TW (1) TWI738864B (en)
WO (1) WO2018050686A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE49687E1 (en) 2014-09-09 2023-10-10 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
WO2016197027A1 (en) 2015-06-04 2016-12-08 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with mll proteins
KR102419524B1 (en) 2016-03-16 2022-07-08 쿠라 온콜로지, 인크. Cross-linked bicyclic inhibitors of menin-MLL and methods of use
WO2017161028A1 (en) 2016-03-16 2017-09-21 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
MX2019002962A (en) 2016-09-14 2019-07-04 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-mll interaction.
ES2966316T3 (en) 2016-09-14 2024-04-19 Janssen Pharmaceutica Nv Fused bicyclic inhibitors of MENIN-MLL interaction
AU2017376599B2 (en) 2016-12-15 2021-10-07 Janssen Pharmaceutica Nv Azepane inhibitors of menin-MLL interaction
CN110691779B (en) 2017-03-24 2023-10-10 库拉肿瘤学公司 Method for treating hematological malignancies and ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. Substituted inhibitors of menin-mll and methods of use
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
MA51337A (en) * 2017-12-20 2020-10-28 Janssen Pharmaceutica Nv SPIRO EXO-AZA INHIBITORS OF MENIN-MLL INTERACTION
CN112105621B (en) * 2018-03-30 2024-02-20 住友制药株式会社 Optically active bridged cyclic secondary amine derivatives
CN112771055B (en) * 2018-08-08 2023-10-20 住友制药株式会社 Optically active bridged piperidine derivatives
US10815241B2 (en) 2018-08-27 2020-10-27 Sumitomo Dainippon Pharma Co., Ltd. Optically active azabicyclo ring derivative
TWI815954B (en) * 2018-08-27 2023-09-21 日商住友製藥股份有限公司 Chiral azabicyclyl compound derivative
US20220380365A1 (en) * 2019-09-27 2022-12-01 Sumitomo Dainippon Pharma Co., Ltd. Crosslinked optically active secondary amine derivative
JP2024518434A (en) 2021-05-08 2024-05-01 ヤンセン ファーマシューティカ エヌ．ベー． Substituted Spiro Derivatives
EP4334320A1 (en) 2021-05-08 2024-03-13 JANSSEN Pharmaceutica NV Substituted spiro derivatives
AU2022286467A1 (en) 2021-06-01 2024-01-25 Janssen Pharmaceutica Nv SUBSTITUTED PHENYL-1H-PYRROLO[2, 3-c]PYRIDINE DERIVATIVES
EP4347600A1 (en) 2021-06-03 2024-04-10 JANSSEN Pharmaceutica NV Pyridazines or 1,2,4-triazines substituted by spirocyclic amines
KR20240021808A (en) 2021-06-17 2024-02-19 얀센 파마슈티카 엔브이 (R)-N-ethyl-5-fluoro-N-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino for the treatment of diseases such as cancer )-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt
WO2024033479A1 (en) * 2022-08-11 2024-02-15 Remynd N.V. (aza)spiroheptane derivatives for the treatment of neurodegenerative disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010289321A1 (en) 2009-09-04 2012-04-05 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AU2014249233A1 (en) 2013-03-13 2015-09-24 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
CN105732636B (en) * 2014-12-30 2020-04-21 广东东阳光药业有限公司 Heteroaromatic compounds and their use in medicine
CN108779116A (en) 2015-12-22 2018-11-09 生命医药公司 The inhibitor of Multiple Endocrine tumor albumen-MLL interactions

Also Published As

Publication number Publication date
CA3033239A1 (en) 2018-03-22
TW201823250A (en) 2018-07-01
WO2018050686A1 (en) 2018-03-22
TWI738864B (en) 2021-09-11

Similar Documents

Publication Publication Date Title
EA201990699A1 (en) SPIROBICYCLIC INhibitors of the MENIN – MLL INTERACTION
MX2019002959A (en) Fused bicyclic inhibitors of menin-mll interaction.
EA201991448A1 (en) AZEPAN INTERACTION INHIBITORS MENIN-MLL
EA201792529A1 (en) Thyrosine Kinase Inhibitors
MX2019002962A (en) Spiro bicyclic inhibitors of menin-mll interaction.
EA201891489A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING AMORPHOUS LENALIDOMIDE AND ANTIOXIDANT
EA201692079A1 (en) INHIBITORS OF LYSINE-SPECIFIC DEMETILASE-1
EA201792229A1 (en) Bromodomain inhibitors
CL2018001226A1 (en) Dihydroimidazopirazinone derivatives used in cancer treatment
EA201792548A1 (en) 4-HYDROXY-3- (HETEROARIL) PYRIDIN-2-ONE APJ AGONISTS FOR APPLICATION IN THE TREATMENT OF CARDIOVASCULAR DISEASES
EA201891974A1 (en) INHIBITORS OF BINDING WDR5 PROTEIN WITH PROTEINS
EA201690734A1 (en) Bromodomain inhibitors
EA202090098A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
EA201892123A1 (en) 6-HYDROXY-4-OXO-1,4-DIHYDROPYRIMIDIN-5-CARBOXAMIDE AS APJ AGONISTS
EA201691845A1 (en) PHARMACEUTICAL COMPOSITIONS OF THERAPEUTICALLY ACTIVE COMPOUNDS
MX2020006594A (en) Exo-aza spiro inhibitors of menin-mll interaction.
EA201891336A1 (en) Heteroarylhydroxypyrimidinones as agonists of the APJ receptor
EA201692285A1 (en) EZH2 INHIBITORS FOR TREATING LYMPHOMA
EA201690159A1 (en) METHODS AND COMPOSITIONS FOR CANCER TREATMENT
EA201890331A1 (en) PYRIDINODICARBOXAMIDES FOR APPLICATION AS BROMODOUM INHIBITORS AS
EA201592108A1 (en) HETEROCYCLIC COMPOUNDS AS HEDGEHOG SIGNAL PATH INHIBITORS
EA201692049A1 (en) Heteroaryl substituted heterocyclic sulfones
TR201908265T4 (en) Fused 1,4-dihydrodioxine derivatives as inhibitors of heat shock transcription factor 1.
EA201690783A1 (en) SUBSTANCES, PHARMACEUTICAL COMPOSITION AND METHODS OF APPLICATION IN THE TREATMENT OF INFLAMMATORY DISEASES
BR112022008365A2 (en) CD73 INHIBITORS